Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
← catalyst calendarNCT06311708 · readout in 1,318 d
Sponsored by Tenaya Therapeutics (industry) · TNYA — their whole pipeline →. With University of California, San Francisco, Brigham and Women's Hospital, New York University, University of Colorado, Denver and 17 more.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
21
Countries
France, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-31 | actual | When the study began enrolling |
| Primary completion | 2030-03-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Arrhythmogenic Right Ventricular Cardiomyopathy
Primary outcome
what the primary-completion date above is the date OFInvestigate the seroprevalence of pre-existing antibodies to AAV9 in patients with PKP2-associated ARVC
measured 5 years
Permalink · TNYA's whole pipeline · Catalyst calendar · Every registered study · What changed